Testing a new injectable HIV prevention medication with different hormone use

This trial is testing cabotegravir (Apretude), an FDA-approved injectable medication given every two months to prevent HIV infection. Researchers want to understand how well this medication reaches the tissues in the rectum and genital areas where HIV transmission actually occurs, and whether using hormone therapies affects how the medication works in your body.

While this medication has proven effective at preventing HIV in large studies, researchers still have important unanswered questions about how it penetrates the specific tissues where HIV enters the body and how it might interact with hormone therapies that some people use. This study will directly measure the medication's levels in blood, tissue samples, and genital secretions to fill these knowledge gaps.